Trials / Conditions / Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

28 registered clinical trials studyying Chronic Inflammatory Demyelinating Polyradiculoneuropathy — 10 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Tongji NADs Cohort NCT07333196	Tongji Hospital	—
Recruiting	A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP NCT07091630	argenx	Phase 3
Recruiting	Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study NCT07264426	argenx	—
Recruiting	Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD1 NCT06939166	Tianjin Huanhu Hospital	EARLY_Phase 1
Recruiting	Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases NCT07022197	Tianjin Medical University General Hospital	Phase 1 / Phase 2
Not Yet Recruiting	Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System. NCT06485232	Xuanwu Hospital, Beijing	EARLY_Phase 1
Recruiting	Our Study Aims to Determine if Nerve Alterations in Acute GBS and CIDP Detectable by Ultrasound Match Electrod NCT06615622	Assiut University	—
Recruiting	Biomarkers in Autoimmune Disease of Nervous System NCT06502015	Tongji Hospital	—
Recruiting	A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyne NCT06290128	Sanofi	Phase 3
Unknown	Genetic Architecture of Chronic Inflammatory Demyelinating Polyradiculoneuropathy NCT06325878	Istituto Clinico Humanitas	N/A
Withdrawn	InertiaLocoGraphy as a Biomarker of Immunoglobulin Therapy Efficacy in Chronic Inflammatory Demyelinating Poly NCT04529291	Fondation Hôpital Saint-Joseph	N/A
Withdrawn	Evaluation of the Diagnostic Contributions of Nerve Ultrasound in Chronic Inflammatory Demyelinating Polyneuro NCT05257733	Centre Hospitalier Universitaire de Nīmes	—
Completed	Role of High Frequency Ultrasound in Demyelinating Polyneuropathies NCT04978623	Centre Hospitalier Universitaire de Nice	—
Completed	Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) NCT04658472	Bioverativ, a Sanofi company	Phase 2
Completed	Do IgG Level Variations in CIDP and MMN Patients Following Initial Intravenous IVIg Treatment Correlate With U NCT04356781	Walton Centre NHS Foundation Trust	—
Recruiting	Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the N NCT04561557	Tongji Hospital	EARLY_Phase 1
Completed	Study of Electrical Prognostic Factors of Response to Intravenous Immunoglobulin Treatment in Chronic Inflamma NCT03967899	Fondation Hôpital Saint-Joseph	—
Active Not Recruiting	Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial NCT03584022	Mayo Clinic	N/A
Completed	Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP NCT02955355	Baxalta now part of Shire	Phase 3
Completed	Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demy NCT02892890	Assistance Publique Hopitaux De Marseille	N/A
Completed	A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculo NCT02549170	Baxalta now part of Shire	Phase 3
Terminated	Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study NCT02317562	Laboratoire français de Fractionnement et de Biotechnologies	Phase 3
Completed	Efficacy and Safety Study of I10E in Treatment of Patients With CIDP NCT02293460	Laboratoire français de Fractionnement et de Biotechnologies	Phase 3
Unknown	Transcriptome Analysis of the Peripheral Blood in CIDP NCT02404298	Assistance Publique - Hôpitaux de Paris	N/A
Completed	MRI in Diagnosing and Monitoring CIDP NCT02017769	University of Aarhus	—
Completed	Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Dem NCT01625182	Novartis Pharmaceuticals	Phase 3
Terminated	Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP NCT01225276	Octapharma	Phase 2 / Phase 3
Completed	Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP NCT00099489	Biogen	Phase 2